ABSTRACT

BISPECIFIC DOMAIN ANTIBODIES TARGETING SERUM ALBUMIN AND GLP-1 OR PYY

Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.

No Figure to accompany abstract.